Comparative Pharmacology
Head-to-head clinical analysis: BREVIBLOC IN PLASTIC CONTAINER versus ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREVIBLOC IN PLASTIC CONTAINER versus ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER.
BREVIBLOC IN PLASTIC CONTAINER vs ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Esmolol is a cardioselective beta-1 adrenergic receptor antagonist with minimal intrinsic sympathomimetic activity and membrane-stabilizing properties. At therapeutic doses, it blocks beta-1 receptors in the myocardium, decreasing heart rate, myocardial contractility, and AV conduction velocity, leading to reduced cardiac output and myocardial oxygen demand.
Selective beta-1 adrenergic receptor antagonist with rapid onset and short duration of action; reduces heart rate, myocardial contractility, and blood pressure; no intrinsic sympathomimetic activity or membrane stabilizing activity.
Initial loading dose: 500 mcg/kg IV over 1 minute, followed by continuous IV infusion of 50 mcg/kg/min for 4 minutes; if inadequate response, repeat loading dose and increase infusion by 50 mcg/kg/min increments up to 200 mcg/kg/min. Maintenance: 25-200 mcg/kg/min continuous IV infusion.
Intravenous loading dose: 500 mcg/kg over 1 minute, followed by maintenance infusion: 50 mcg/kg/min for 4 minutes; if adequate response not achieved, repeat loading dose and increase maintenance infusion by 50 mcg/kg/min increments up to 200 mcg/kg/min.
None Documented
None Documented
Terminal elimination half-life is approximately 9 minutes (range 4–15 minutes) for the parent drug, leading to rapid offset of effect. The half-life of the metabolite ASL-8123 is about 3.7 hours.
Terminal elimination half-life is approximately 9 minutes (range 6–12 min) in healthy adults; prolonged to 15–20 min in hepatic impairment. Clinical context: rapid offset allows precise titration.
Elimination primarily via red blood cell esterases; renal excretion of unchanged drug is less than 1% of dose. Metabolite ASL-8123 is inactive and renally excreted.
Rapid hydrolysis by esterases in blood and tissues to inactive acid metabolite (ASL-8123) and methanol. Less than 2% excreted unchanged in urine. Renal elimination of metabolite accounts for >80% of dose; <5% fecal.
Category C
Category A/B
Beta-Blocker
Beta-Blocker